The global Tissue Engineering Market was valued at $6.2 Billion in 2017 and is forecast to grow at a modest 16.15 % CAGR between 2018 and 2025, culminating in 2025 global sales of $ x.x Billion.
Tissue engineering deal with the development of biological substitutes capable of replacing diseased or damaged tissue in humans.
This activity is complex as the body uses its own tissue along with engineered tissue to recreate cells and rebuild tissues and organs. “tissue engineering” and “regenerative medicine” has become largely interchangeable. This field continues to evolve. In addition to medical applications, non-therapeutic applications include using tissues as biosensors to detect biological or chemical threat agents and tissue chips that can be used to test the toxicity of an experimental medication.
The ideal material for bone tissue engineering should be osteoconductive as well as osteoinductive. It is inert and allows the ingrowth of host tissue. Now a day’s nanoscale biomaterials are in demand due to its ability upgrade as hard tissue engineering materials. Purpose of tissue engineering is to control the cellular interaction with synthetic material.
We have segmented the Tissue Engineering market by application type into Orthopedics, GI, Gynecology, Cancer, Cord Blood & Cell Banking, Dental, Skin/Integumentary. WE are observing a greater adaptation of traditional Tissue Engineering in recent past years as cheaper compared to advanced Tissue Engineering. However advanced Tissue Engineering is expected to have increased adaptation during the forecast period.
Spine tissue engineering, musculoskeletal and orthopedics are major part of the overall market. Fracture alone (Approx. 20 million) account for financial burden on of USD 65 billion in U.S. alone. We are expecting cardiac tissue engineering to grow exponentially during the forecasting period.
There is different type of Tissue Engineering Materials are:
- Biologically Derived Materials
- Nano-Fibrous Materials
- Composite Materials
The key market participants include Allergan, Medtronic, Zimmer Biomet, Stryker Corporation, Organogenesis Inc., Acelity, Athersys Inc., Tissue Regenix Group Plc, RTI Surgical Inc, Osiris Therapeutics, Biotime Inc, B. Braun, International Stem Cell.